Welcome to our dedicated page for Orchestra BioMed Holdings SEC filings (Ticker: OBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Orchestra BioMed Holdings, Inc. filings document the governance, financing and material agreements of a biomedical company developing AVIM Therapy and Virtue SAB through strategic medical-device partnerships. Current reports describe revenue participation rights, strategic financing, distribution and right-of-first-refusal arrangements, underwritten common stock and pre-funded warrant offerings, investor presentations, and other business updates.
Proxy materials cover board elections, auditor ratification, executive compensation votes, equity and employee stock purchase plans, and related annual-meeting governance. The filing record also includes compensatory-arrangement disclosures for executive bonus plans, registration-statement references, exhibit filings and capital-structure disclosure tied to its cardiovascular product candidates.
Perceptive Advisors LLC and affiliated entities, already a >10 % shareholder of Orchestra BioMed Holdings (OBIO), filed Form 4 disclosing additional purchases on 1 Aug 2025.
- Acquired 700,000 common shares at $2.75 per share through the issuer’s registered public offering (transaction code “P”).
- Acquired 1,500,000 pre-funded warrants (exercise price $0.0001; purchase price $2.7499) that are immediately exercisable, subject to a beneficial-ownership cap.
- Following the transactions, indirect beneficial ownership stands at 5,292,556 common shares and 1,500,000 warrants.
- Filers listed are Perceptive Advisors LLC (investment manager), Perceptive Life Sciences Master Fund Ltd., and Joseph Edelman (managing member). No dispositions were reported.
The filing signals continued capital commitment by a significant insider during the public offering.
Orchestra BioMed Holdings (OBIO) – Form 4 insider activity
On 08/04/2025, Chief Executive Officer & Chairperson David P. Hochman purchased 20,000 common shares in the company’s underwritten public offering at $2.75 per share, investing $55,000. The shares were bought indirectly through the DPH 2008 Trust, raising that trust’s position to 349,331 shares.
Following the acquisition, Hochman’s total beneficial ownership stands at 903,931 shares, consisting of 545,460 shares held directly and 358,471 shares held through five family trusts (DPH 2008, Solomon Ascher 2019, Hannah 2019, Judah Herman 2019, NSH 2008). No shares were sold and no derivative securities were reported in the filing.
The transaction increases the CEO’s economic exposure and signals participation in the recent capital raise, but the filing contains no financial results, guidance, or other operational disclosures.
Orchestra BioMed (OBIO) filed an 8-K announcing a $40 m underwritten equity offering and a concurrent $16.2 m private placement.
The public deal comprises 9.4 m common shares priced at $2.75 and 5.1 m pre-funded warrants priced at $2.7499; underwriters (Piper Sandler, TD Securities) hold a 30-day option for 2.18 m additional shares. Pre-funded warrants carry a $0.0001 exercise price and a 9.99 % beneficial-ownership cap, adjustable to 19.99 % on 61-days’ notice.
Immediately after the offering closed on 4 Aug 2025, the company sold 5.9 m shares to Ligand and a Medtronic affiliate in a PIPE, and issued Ligand a warrant for up to 2 m shares at $3.67. Aggregate gross proceeds reach roughly $56 m before fees.
OBIO plans to deploy the capital to advance its atrioventricular interval modulation therapy (BACKBEAT study) and Virtue Sirolimus AngioInfusion Balloon programs, and for general corporate purposes. The filing also includes customary indemnities, legal opinions and forward-looking-statement disclaimers.
Orchestra BioMed Holdings (OBIO) director Chris Cleary received new equity compensation grants on June 24, 2025. The awards consist of:
- 12,422 Restricted Stock Units (RSUs) with a $0 exercise price, bringing total direct ownership to 22,577 shares
- 36,797 Stock Options with an exercise price of $3.22 per share, expiring June 24, 2035
Both the RSUs and stock options will vest in a single installment at the earlier of: (1) one-year anniversary of grant date or (2) the 2026 Annual Meeting of Stockholders, subject to continued service. This Form 4 filing was submitted by Andrew Taylor as attorney-in-fact on June 26, 2025, reflecting standard director compensation arrangements.
Orchestra BioMed Holdings (OBIO) director John Prosper Mack received two equity awards on June 24, 2025:
- 12,422 Restricted Stock Units (RSUs) with a $0 exercise price
- 36,797 Stock Options with an exercise price of $3.22 per share and expiration date of June 24, 2035
Both awards vest in a single installment at the earlier of: (1) one-year anniversary of grant date or (2) the 2026 Annual Meeting of Stockholders, subject to continued service. Following these transactions, Mack directly owns 25,286 shares of common stock and 36,797 stock options. This compensation structure aligns the director's interests with shareholders through both full-value shares and appreciation-only options.
Orchestra BioMed Holdings (OBIO) reported insider trading activity through a Form 4 filing for director Pamela Ann Connealy. On June 24, 2025, Connealy received two equity awards:
- 12,422 Restricted Stock Units (RSUs) with zero exercise price, bringing her total direct ownership to 33,711 shares
- 36,797 Stock Options with an exercise price of $3.22, expiring June 24, 2035
Both awards vest in a single installment at the earlier of: (1) one-year anniversary of the grant date, or (2) the 2026 Annual Meeting of Stockholders, subject to continuous service. The transaction was executed pursuant to the company's director compensation program, with the filing submitted by Andrew Taylor as attorney-in-fact on June 26, 2025.
Orchestra BioMed Holdings (OBIO) reported insider trading activity for Director Eric S. Fain on June 24, 2025. The transactions include:
- Acquisition of 12,422 restricted stock units (RSUs) at $0, held indirectly through the Fain Living Trust. Each RSU converts to one share of common stock
- Grant of 36,797 stock options with an exercise price of $3.22, held directly
Both the RSUs and stock options will vest in a single installment at the earlier of: (1) one-year anniversary of the grant date or (2) the 2026 Annual Meeting of Stockholders, subject to continuous service. Following these transactions, Fain beneficially owns 53,632 shares indirectly through the trust and 36,797 stock options directly. The Form 4 was filed by Andrew Taylor as attorney-in-fact on June 26, 2025.